{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Merck+Sharp+%26+Dohme+LLC", "query": { "sponsor": "Merck Sharp & Dohme LLC" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1804, "total_pages": 181, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Merck+Sharp+%26+Dohme+LLC&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T07:15:09.265Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05383170", "title": "A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Breast Cancer", "Advanced Melanoma" ], "interventions": [ { "name": "CyPep-1", "type": "DRUG" }, { "name": "Pembrolizumab 25 MG/ML [KEYTRUDA®]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cytovation AS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-03-21", "completion_date": "2024-09-23", "has_results": true, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-06-07T07:15:09.265Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Duarte, California • Detroit, Michigan + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05383170" }, { "nct_id": "NCT00129441", "title": "Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Merck L-830982", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "MALE", "summary": "18 Years to 50 Years · Male only" }, "enrollment_count": 16, "start_date": "2005-08", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2011-10-17", "last_synced_at": "2026-06-07T07:15:09.265Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00129441" }, { "nct_id": "NCT05052723", "title": "Cabozantinib and Pembrolizumab in Metastatic Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joseph Kim", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 21, "start_date": "2022-01-04", "completion_date": "2024-11-05", "has_results": true, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-06-07T07:15:09.265Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05052723" }, { "nct_id": "NCT04312841", "title": "Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Prolymphocytic Leukemia", "Chronic Lymphocytic Leukemia", "Peripheral T-Cell Lymphoma", "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Sezary Syndrome", "T-Cell Prolymphocytic Leukemia" ], "interventions": [ { "name": "Letermovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-09-15", "completion_date": "2024-04-09", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-06-07T07:15:09.265Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04312841" }, { "nct_id": "NCT05335005", "title": "MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "End-Stage Renal Disease", "Kidney Failure, Chronic" ], "interventions": [ { "name": "MK-2060", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 12, "start_date": "2022-05-30", "completion_date": "2023-02-14", "has_results": true, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-06-07T07:15:09.265Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05335005" }, { "nct_id": "NCT03260322", "title": "A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASP8374", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2017-09-08", "completion_date": "2022-05-10", "has_results": false, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-06-07T07:15:09.265Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03260322" }, { "nct_id": "NCT04753879", "title": "Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2021-09-29", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-07T07:15:09.265Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04753879" }, { "nct_id": "NCT02013154", "title": "A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Neoplasms", "Adenocarcinoma of the Gastroesophageal Junction", "Gastroesophageal Cancer", "Squamous Cell Carcinoma", "Gastric Adenocarcinoma" ], "interventions": [ { "name": "DKN-01 150 mg", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "DKN-01 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leap Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2014-05-05", "completion_date": "2021-01-11", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-06-07T07:15:09.265Z", "location_count": 10, "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02013154" }, { "nct_id": "NCT06234605", "title": "A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "HC-7366", "type": "DRUG" }, { "name": "Belzutifan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HiberCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2024-04-29", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-06-07T07:15:09.265Z", "location_count": 20, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06234605" }, { "nct_id": "NCT05064059", "title": "A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "favezelimab/pembrolizumab", "type": "BIOLOGICAL" }, { "name": "regorafenib", "type": "DRUG" }, { "name": "TAS-102", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 441, "start_date": "2021-11-10", "completion_date": "2025-02-21", "has_results": true, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-07T07:15:09.265Z", "location_count": 15, "location_summary": "Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05064059" } ] }